^
    CANCER:

    Gastric Cancer





    Show legend
    Group by Gene:
    Include preclinical:

    PD1 inhibitor
    nivolumab
    pembrolizumab
    sintilimab
    tislelizumab
    		0
    PD1 inhibitor
    camrelizumab
    toripalimab-tpzi
    dostarlimab-gxly
    zimberelimab
    pucotenlimab
    PDR001
    HER2 inhibitor
    trastuzumab
    trastuzumab-anns
    trastuzumab-qyyp
    trastuzumab-dkst
    Zercepac (trastuzumab biosimilar)
    trastuzumab-pkrb
    		1
    HER2 inhibitor
    ZW25
    trastuzumab-dttb
    Her-VAXX
    AST-301
    KN026
    trastuzumab + tucatinib
    tucatinib
    trastuzumab-IFN-β mutein
    5-fluorouracil
    		2
    Thymidylate synthase inhibitor
    capecitabine
    raltitrexed
    PD-L1 inhibitor
    durvalumab
    		3
    PD-L1 inhibitor
    envafolimab
    atezolizumab
    sugemalimab
    avelumab
    4
    DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + capecitabine
    cisplatin + 5-fluorouracil
    5
    VEGFR-2 inhibitor
    ramucirumab
    rivoceranib
    6
    CTLA4 inhibitor
    tremelimumab
    zolbetuximab
    		7
    CLDN18.2 inhibitor
    ZL-1211
    TST001
    AB011
    8
    DNA synthesis inhibitor, DNA cross linking agent, Thymidylate synthase inhibitor
    5-fluorouracil + oxaliplatin
    capecitabine + oxaliplatin
    9
    Thymidine phosphorylase inhibitor
    trifluridine / tipiracil
    10
    Topoisomerase I inhibitor
    irinotecan
    11
    Tubulin polymerization promoter, Bcl2 inhibitor
    paclitaxel
    carboplatin + paclitaxel
    12
    DNA synthesis inhibitor, DNA cross linking agent
    oxaliplatin
    13
    DNA synthesis inhibitor, Topoisomerase I inhibitor
    cisplatin + irinotecan
    14
    Thymidylate synthase inhibitor, Topoisomerase I inhibitor
    5-fluorouracil + irinotecan
    15
    FGFR2b inhibitor
    AMG 552
    16
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    fam-trastuzumab deruxtecan-nxki
    SHR-A1811
    FGFR inhibitor
    infigratinib
    futibatinib
    		17
    FGFR inhibitor
    ABSK091
    ARQ 087
    KIN-3248
    Debio 1347
    nivolumab + ramucirumab
    camrelizumab + rivoceranib
    		18
    VEGFR-2 inhibitor, PD1 inhibitor
    tislelizumab + rivoceranib
    pembrolizumab + ramucirumab
    toripalimab-tpzi + rivoceranib
    19
    VEGF-A inhibitor
    bevacizumab
    20
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    cadonilimab
    savolitinib
    tepotinib
    ARQ 197
    RG3638
    		21
    c-MET inhibitor
    S95027
    savolitinib + capmatinib
    AMG 102
    SGX523
    JNJ-38877605
    pembrolizumab + trastuzumab
    pembrolizumab + margetuximab
    nivolumab + trastuzumab
    		22
    HER2 inhibitor, PD1 inhibitor
    margetuximab + retifanlimab-dlwr
    tislelizumab + ZW25
    trastuzumab + camrelizumab
    trastuzumab + tislelizumab
    23
    PI3Kβ inhibitor
    AZD8186
    GSK2636771
    24
    DKK1 protein inhibitor
    DKN-01
    25
    Gastrin-17 inhibitor
    PAS
    26
    TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
    larotrectinib
    27
    VEGFR-2 inhibitor, HER2 inhibitor
    trastuzumab + ramucirumab
    trastuzumab + ramucirumab + tucatinib
    EGFR inhibitor
    cetuximab
    		28
    EGFR inhibitor
    GC-1118A
    WZ4002
    CL-387785
    CLDN18.2-targeted CAR-T immunotherapy
    		29
    CLDN18.2-targeted CAR-T immunotherapy
    IBI-345
    CT041
    30
    DNA synthesis inhibitor
    cisplatin
    31
    VEGFR inhibitor, FGFR1 inhibitor, PD1 inhibitor
    toripalimab-tpzi + surufatinib
    32
    Microtubule inhibitor
    cabazitaxel
    33
    ALK inhibitor
    crizotinib
    34
    STAB1 inhibitor
    bexmarilimab
    pazopanib
    		35
    Multi-tyrosine kinase inhibitor
    regorafenib
    ponatinib
    nintedanib
    36
    PIK3CA inhibitor
    CYH33
    alpelisib
    PARP inhibitor
    		37
    PARP inhibitor
    olaparib
    ABT-888
    38
    DKK1 protein inhibitor, PD1 inhibitor
    tislelizumab + DKN-01
    pembrolizumab + DKN-01
    39
    PD-L1 inhibitor, TGF-β R2 kinase inhibitor
    SHR-1701
    40
    PD1 inhibitor, LAG-3 inhibitor
    sintilimab + IBI110
    41
    CLDN18.2 inhibitor, CD137 agonist
    TJ-CD4B
    42
    mTOR inhibitor, mTORC2 inhibitor
    AZD2014
    43
    AKT inhibitor
    capivasertib
    44
    CD19-targeted CAR-T immunotherapy
    AT101
    45
    HER2-targeted antibody-drug conjugate, Tubulin inhibitor
    A166
    46
    BRAF inhibitor, BRAF V600E inhibitor
    vemurafenib
    47
    HER2 inhibitor, HER3 inhibitor
    MCLA-128
    48
    PD-L1 inhibitor, CD137 agonist
    PM1003
    49
    PD-L1 inhibitor, Multi-tyrosine kinase inhibitor
    durvalumab + cabozantinib tablet
    anlotinib + APL-502
    50
    VEGFR-2 inhibitor, HER2 inhibitor, CD47 inhibitor
    trastuzumab + ramucirumab + ALX148
    51
    NK cell stimulant
    CYNK-101
    52
    HER2 inhibitor, CD47 inhibitor
    D3L-001
    53
    PD-L1 inhibitor, HER2 inhibitor
    trastuzumab + avelumab
    54
    Aromatase inhibitor
    letrozole
    55
    HER2 inhibitor, HER2 dimerization inhibitor
    trastuzumab + pertuzumab
    56
    MEK inhibitor, BRAF inhibitor
    trametinib + dabrafenib
    57
    RET inhibitor
    selpercatinib
    58
    ATR inhibitor
    M6620
    SC0245
    59
    PD1 inhibitor, CTLA4 inhibitor, CD47 inhibitor
    cadonilimab + AK117
    60
    HER2 inhibitor, γδ TCR modulator
    Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T
    61
    PD-L1 inhibitor, PARP inhibitor
    olaparib + durvalumab
    62
    Tubulin polymerization promoter
    carboplatin
    63
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + regorafenib
    ECF
    TPF
    DOF
    TCF
    FP
    CaT
    		64
    Chemotherapy
    FOLFIRI
    CAPOX
    DP
    FLOT
    IP
    FOLFOX
    TEX
    65
    Immunotherapy
    Immunotherapy
    66
    CLDN18.2-targeted antibody-drug conjugate
    CLDN18.2-targeted antibody-drug conjugate
    ATG-022
    67
    EZH2 inhibitor
    EZH2 inhibitor
    68
    c-MET-targeted CAR-T immunotherapy
    c-MET-targeted CAR-T immunotherapy
    69
    FGFR21 inhibitor
    FGFR21 inhibitor
    70
    PD-L1-targeted CAR-T immunotherapy
    PD-L1-targeted CAR-T immunotherapy
    disitamab vedotin
    ado-trastuzumab emtansine
    JNJ-0683
    		71
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ZW49
    PF-06804103
    MRG002
    XMT-1522
    72
    PD-L1 inhibitor, CTLA4 inhibitor
    durvalumab + tremelimumab
    73
    Microtubule stabilizer, Tubulin polymerization promoter, Topoisomerase I inhibitor
    docetaxel + irinotecan
    74
    Tubulin polymerization promoter, Bcl2 inhibitor, Thymidylate synthase inhibitor
    paclitaxel + capecitabine
    paclitaxel + 5-fluorouracil
    75
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor, Thymidylate synthase inhibitor
    cisplatin + docetaxel + 5-fluorouracil
    76
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor
    cisplatin + paclitaxel
    77
    Microtubule stabilizer, Tubulin polymerization promoter, Thymidylate synthase inhibitor
    carboplatin + docetaxel + 5-fluorouracil
    78
    Microtubule stabilizer, Tubulin polymerization promoter, DNA synthesis inhibitor
    cisplatin + docetaxel
    79
    Microtubule stabilizer, Tubulin polymerization promoter
    docetaxel
    AZD0901
    		80
    CLDN18.2-targeted antibody-drug conjugate, Microtubule inhibitor
    EO-3021
    BMS-986476
    pyrotinib
    		81
    HER2 inhibitor, HER4 inhibitor, EGFR inhibitor
    ASLAN001
    afatinib
    neratinib
    82
    TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
    entrectinib
    83
    CEACAM5-targeted antibody-drug conjugate, Microtubule inhibitor
    SAR408701
    84
    Tubulin polymerization promoter, HSP70 inhibitor, Bcl2 inhibitor
    paclitaxel + minnelide
    85
    PDGFR inhibitor, Bcr-abl tyrosine kinase inhibitor, c-KIT inhibitor
    imatinib
    86
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    87
    HER2 inhibitor, EGFR inhibitor
    lapatinib
    88
    FGFR2 inhibitor, FGFR inhibitor, FGFR1 inhibitor, FGFR3 inhibitor, FGFR4 inhibitor
    erdafitinib
    89
    c-MET inhibitor, CSF-1R inhibitor, Src kinase inhibitor
    TPX-0022
    90
    PD-L1 inhibitor, VEGF-A inhibitor, TGF-β R2 kinase inhibitor
    bevacizumab + SHR-1701
    91
    VEGF-A inhibitor, Folate receptor 1-targeted antibody-drug conjugate, Microtubule inhibitor
    bevacizumab + mirvetuximab soravtansine-gynx
    92
    TGFβ inhibitor, PD-L1 inhibitor
    M7824
    93
    HER2 inhibitor, HER4 inhibitor, PD1 inhibitor, EGFR inhibitor
    camrelizumab + pyrotinib
    94
    PD-L1 inhibitor, HER2 inhibitor, CTLA4 inhibitor
    KN046 + KN026
    95
    CLDN18.2-targeted antibody-drug conjugate, DNA replication inhibitor
    SOT102
    96
    CLDN18.2 inhibitor, CD3 agonist
    ASP2138
    AZD5863
    97
    Tubulin polymerization promoter, DNA synthesis inhibitor, Bcl2 inhibitor, Thymidylate synthase inhibitor
    cisplatin + paclitaxel + capecitabine
    98
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    99
    ADAM9-targeted antibody-drug conjugate, Microtubule inhibitor
    IMGC936
    100
    HER2 inhibitor, HER4 inhibitor, CDK4 inhibitor, EGFR inhibitor, CDK6 inhibitor
    pyrotinib + dalpiciclib
    101
    CD137 agonist, HER2 inhibitor
    PRS-343
    102
    VEGFR-2 inhibitor, Caprin-1 inhibitor
    ramucirumab + TRK-950
    103
    ATR inhibitor, PD-L1 inhibitor
    durvalumab + AZD6738
    104
    HER2 inhibitor, ALK inhibitor
    trastuzumab + crizotinib
    105
    CLDN18.2 inhibitor, PD-L1 inhibitor
    Q-1802
    106
    SLC44A4-targeted antibody-drug conjugate, Microtubule inhibitor
    ASG 5ME
    107
    Protein synthesis inhibitor, HER2 inhibitor
    MT-5111
    108
    TIGIT inhibitor, PD1 inhibitor
    pembrolizumab + MK-7684
    zimberelimab + AB154
    109
    PD1 inhibitor, PORCN inhibitor, Wnt signalling pathway inhibitor
    pembrolizumab + CGX1321
    110
    c-MET-targeted antibody-drug conjugate, DNA replication inhibitor
    BYON3521
    111
    PD1 inhibitor, HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    nivolumab + fam-trastuzumab deruxtecan-nxki
    112
    VEGFR inhibitor, PD1 inhibitor
    sintilimab + fruquintinib
    vorinostat
    		113
    HDAC inhibitor
    MGCD0103
    SB939
    114
    HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor
    entinostat
    115
    MYC inhibitor
    WB100
    116
    KRAS G12C inhibitor
    APG-1842
    117
    CDK9 inhibitor
    KB-0742
    118
    HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor, WEE1 inhibitor
    fam-trastuzumab deruxtecan-nxki + AZD1775
    119
    ALPP-targeted antibody-drug conjugate, ALPPL2-targeted antibody-drug conjugate, Microtubule inhibitor
    SGN-ALPV
    120
    HER2-targeted antibody-drug conjugate, STING agonist
    XMT-2056
    121
    TGM2 inhibitor
    MD102
    122
    AKT3 inhibitor, AKT1 inhibitor, AKT inhibitor, p70S6K inhibitor
    DIACC3010
    123
    Bcr-abl tyrosine kinase inhibitor, HER2 inhibitor, HER4 inhibitor, EGFR inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib + neratinib
    124
    Cyclin modulator
    ON 013105
    125
    FGFR2b inhibitor, FGF7 inhibitor
    GB2102
    126
    CLDN18.2 inhibitor, CD137 agonist, PD1 inhibitor
    nivolumab + TJ-CD4B
    127
    CDK2 inhibitor
    INX-315
    128
    HER2 inhibitor, CD47 inhibitor, HER2 dimerization inhibitor
    pertuzumab + D3L-001
    129
    MUC1-targeted antibody-drug conjugate, HER3-targeted antibody-drug conjugate
    DM002
    130
    HER2 inhibitor, EGFR inhibitor, Multi-tyrosine kinase inhibitor
    AEE788
    131
    PI3K inhibitor
    MEN1611
    132
    FGFR inhibitor, c-MET inhibitor
    WXSH0011
    133
    BET inhibitor, BRD4 inhibitor
    SRA515
    134
    Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, c-KIT inhibitor, PDGFR β antagonist, EphA2 receptor antagonist
    dasatinib
    135
    STAT3 inhibitor
    BBI608
    136
    c-MET-targeted antibody-drug conjugate, 5T4-targeted antibody-drug conjugate
    DM004
    137
    PLK1 inhibitor
    NBL-001
    138
    PLK1 inhibitor, BRD4 inhibitor
    BI2536
    139
    HER2 inhibitor, HER2-targeted antibody-drug conjugate, Microtubule inhibitor
    ado-trastuzumab emtansine + AST-301
    140
    TROP-2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    sacituzumab govitecan-hziy
    141
    Microtubule inhibitor, TROP-2-targeted antibody-drug conjugate
    LCB84
    142
    Bcl2 inhibitor, Bcl-xL inhibitor
    APG-1252
    143
    Macrophage modulator
    HF-CAR-PMs
    144
    PI3K inhibitor, mTOR inhibitor
    RTB101
    145
    MCL1 inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor
    AT 101
    146
    MAT2A inhibitor
    IDE397
    147
    HER2 inhibitor, EGFR inhibitor, Bcl2 inhibitor, Bcl-xL inhibitor
    lapatinib + APG-1252
    148
    HER2 inhibitor, NK cell stimulant
    trastuzumab + CYNK-101
    149
    p53 reactivator
    PC14586
    150
    HER2-targeted antibody-drug conjugate, Microtubule inhibitor, HER2 dimerization inhibitor
    pertuzumab + ado-trastuzumab emtansine
    151
    CDK4 inhibitor, CDK6 inhibitor
    abemaciclib
    152
    Topoisomerase II inhibitor, HER2 inhibitor, HER2-targeted antibody-drug conjugate
    trastuzumab + MM-302
    153
    c-MET inhibitor, HER2 inhibitor
    trastuzumab + savolitinib
    154
    5T4-targeted antibody-drug conjugate, Microtubule inhibitor
    ASN004
    155
    c-MET-targeted antibody-drug conjugate, Topoisomerase I inhibitor
    HRA00129-C004
    156
    ICAM-1-targeted CAR-T immunotherapy
    AIC100
    157
    DNMT inhibitor
    decitabine
    158
    AKT3 inhibitor, HER2 inhibitor, AKT1 inhibitor, AKT inhibitor, p70S6K inhibitor
    trastuzumab + DIACC3010
    No biomarker
    HER-2 negative
    HER-2 positive
    HER-2 expression
    HER-2 overexpression
    HER-2 amplification
    HER-2 positive + HER-2 amplification
    HER-2 underexpression
    HER-2 mutation
    HER-2 expression + HER-2 amplification
    HER-2 mutation + HER-2 positive
    HER-2 S310Y
    HER-2 L755S
    HER-2 V777L
    HER-2 T862A
    HER-2 1899‐1G>A
    HER-2 expression + HER-2 D769H
    HER-2 expression + HER-2 L869R
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 amplification
    PD-L1 underexpression
    MSI-H/dMMR
    CLDN18.2 expression
    CLDN18.2 positive
    CLDN18.2 overexpression
    CLDN18 fusion
    CLDN18.2 underexpression
    MET amplification
    FGFR2 fusion
    MET mutation
    FGFR2 amplification
    FGFR2b overexpression
    MET overexpression
    FGFR2b expression
    FGFR2 mutation
    MET exon 14 mutation
    FGFR2b positive
    FGFR2 overexpression
    MET expression
    MET positive
    FGFR2 N549K
    HER-2 negative + PD-L1 expression
    HER-2 positive + PD-L1 expression
    HER-2 amplification + PD-L1 expression
    PD-L1 expression + HER-2 overexpression
    CLDN18.2 positive + HER-2 negative
    CLDN18.2 expression + HER-2 negative
    DKK1 overexpression
    EGFR overexpression
    HER-2 expression + TMB-H
    TMB-H + HER-2 positive
    EGFR mutation
    EGFR amplification
    HER-2 elevation + TMB-H
    HER-2 elevation + TMB-L
    VEGFA elevation
    NRP1 elevation
    KDM6A mutation
    FGFR2b overexpression + HER-2 negative
    VSNL1 underexpression + CD44 underexpression
    PIK3CA mutation
    CEACAM5 positive
    CEACAM5 expression
    PIK3CA E545K
    CEACAM5 overexpression
    PIK3CA amplification
    VEGFA overexpression
    KDM6A underexpression
    PIK3CA E542K
    NTRK3 fusion
    TMB-H
    BRAF V600E
    ERBB3 V104L + HER-2 negative
    TP53 mutation
    IL6 elevation
    ATM underexpression
    ATM mutation
    EGFR amplification + ERBB2 amplification
    IL6 expression
    PD-1 expression
    EGFR expression + HER-2 expression
    FGFR3 mutation
    TP53 wild-type
    PD-1 overexpression
    ERBB3 V104L
    FGFR3 amplification
    TP53 Y220C
    ATM expression
    TMB-L
    ATM overexpression
    TP53 R175H
    TNFA-L
    CLDN18-ARHGAP fusion
    FGFR1 amplification
    MSI-H/dMMR + POLE mutation
    POLD1 mutation
    POLE mutation
    CCKBR expression
    ERBB4 mutation + HER-2 positive
    HLA-A*02
    PIK3R1 M326I
    NF1 mutation + HER-2 positive
    IFNG-L
    ITGAM overexpression + LAG3 overexpression
    ITGAM overexpression + CTLA4 overexpression
    PMS2 mutation
    CPEB1 underexpression
    ACTA2 underexpression
    MLH1 mutation
    CAPRIN-1 expression
    PIK3CB mutation
    RSPO3 fusion
    IL2 expression
    PMS2 mutation + MLH1 mutation
    MSH2 mutation
    MFSD2A overexpression
    SLC44A4 expression
    INHBA overexpression
    PDGFRA mutation
    KIT exon 11 mutation
    VEGFC elevation
    CFB overexpression
    MSH6 mutation
    RICTOR amplification
    ER positive
    MSI-H/dMMR + MLH1 negative + PMS2 negative
    HER-2 amplification + MET amplification
    PTEN deletion
    ADAM9 expression
    POLD2 mutation
    PMS1 mutation
    MSH3 mutation
    MLH3 mutation
    TYMS expression
    LAG3 expression
    RET fusion
    TNFRSF4 expression
    TGFB1 elevation
    HRD
    FOLR1 overexpression
    NTRK1 fusion
    ATRX mutation
    ATR mutation
    NTRK2 fusion
    ARID1A mutation
    ICAM1 elevation
    CXCL8 elevation
    TET1 mutation
    WIF1 unmethylation
    RASSF1 methylation
    FGFR3-TACC3 fusion
    CTAG1A expression
    SMARCA4 mutation
    NQO1 overexpression
    PIK3CA mutation + HER-2 positive
    PIK3R1 mutation + HER-2 positive
    PIK3C3 mutation + HER-2 positive
    GAST expression
    MET expression + HER-2 expression
    PTEN mutation
    ACTA2 overexpression
    PDGFRA D842Y
    PDGFRA D846Y
    PDGFRA DI842_843IM
    PDGFRA Y849K
    FGFR1 overexpression
    PDGFRA D842V
    FGFR1 mutation
    ICAM1 overexpression
    KIT exon 9 mutation
    ARID1A deletion
    PDGFRA exon 12 mutation
    PDGFRA HDSN845_848P
    PDGFRA N659K
    PDGFRA N848K
    PDGFRA RD841_842KI
    MET overexpression + HER-2 overexpression
    IFNG 6-gene signature
    18-gene expanded immune signature
    S100A10 overexpression
    FGFR overexpression
    MUS81 overexpression
    STAT3 expression
    NFKB1 expression
    HER-2 overexpression + CCNE1 amplification
    CCNA2 expression
    ALPP expression
    Chr del(13)(q12.12)
    PTEN mutation + MSI-H/dMMR
    MSI-H/dMMR + TMB-L
    CRKL amplification
    SNHG5 overexpression
    HER-2 overexpression + PTEN deletion
    CEACAM6 overexpression
    CCNE1 amplification
    FGFR4 amplification
    SKAP1 overexpression
    FGFR4 mutation
    CDKN2B deletion
    CD47 positive + HER-2 positive
    CDKN2A deletion
    MDM4 amplification
    MDM2 amplification
    VEGFB overexpression
    Chr amplification(11)(q13)
    TGM2 overexpression
    BCL2 overexpression + MCL1 overexpression
    BCAR4 overexpression
    TUBB3 overexpression
    MAP3K1 rs889312
    MTAP deletion
    TPBG expression + MET expression
    GPR176 overexpression
    TACC2-FGFR2 fusion
    KRAS mutation + HER-2 positive
    MAP3K10 R304C
    MAP3K10 H211R
    MAP3K10 A30E
    ERBB3 expression + MUC1 expression
    TROP2 expression
    LDH elevation
    ALPG expression
    CDKN2A promoter methylation
    HER-2 positive + GATA6 amplification
    HER-2 positive + APC mutation
    HER-2 positive + MYC amplification
    KRAS mutation
    MTA2 expression
    TPBG underexpression + HER-2 overexpression
    TGFBR2 P525L
    TGFBR2 P129Afs*3
    TGFBR2 E269*
    RHOA L57V
    KRAS G12R
    CMTM4 expression + PD-L1 expression
    RHOA D45N
    RHOA L69P
    CMTM6 expression + PD-L1 expression
    APC V2194fs + EGFR amplification + EGFR-SEPTIN14 fusion
    LINC00963 overexpression
    miR-200-b underexpression
    miR-199b overexpression + miR-152 overexpression
    PREX2 M627V
    PREX2 W519G
    PREX2 R1567Q
    MSI-H/dMMR + TMB-H
    IGF2R overexpression
    miR-152 overexpression
    HER-2 positive + CAV1 overexpression
    miR‐223 overexpression
    DNMT3A overexpression
    ATG5 overexpression
    miR-199b overexpression
    BCL2L1 overexpression
    miR-103a underexpression
    miR-200b underexpression + miR-103a underexpression
    SOX17 methylation
    CDH1 deletion
    HOTAIR overexpression
    MET overexpression + MUC5B overexpression
    CD73 overexpression
    MYC overexpression
    CDH1 mutation
    AREG overexpression
    KRAS G12C
    MYC amplification
    miR‑106-a expression
    NLRP6 overexpression
    ARPP19 overexpression
    CD44 expression
    ERBB2 G778A + CCNE1 amplification
    HER-2 underexpression + CCNE1 amplification
    HER-2 amplification + CCNE1 expression